NCT04603508 - Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

August 31, 2025

Conditions

Type 2 Diabetes MellitusDyslipidemia

Interventions

DRUG

BERLIM 25/10 association

Berlim 25/10 association coated tablet.

DRUG

EMPAGLIFLOZIN

Empagliflozin 25 mg coated tablet.

DRUG

ROSUVASTATIN CALCIUM

Rosuvastatin 10 mg coated tablet.

OTHER

BERLIM 25/10 ASSOCIATION PLACEBO

Berlim 25/10 association placebo coated tablet.

OTHER

EMPAGLIFLOZIN PLACEBO

Empagliflozin placebo coated tablet.

OTHER

ROSUVASTATIN CALCIUM PLACEBO

Rosuvastatin placebo coated tablet.